Phaseline

Companies › atai Therapeutics

atai Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VLS-01 buccal film
N-methyl-D-aspartate (NMDA) receptor antagonist
GRIN1Phase 2Treatment Resistant Depression–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06524830VLS-01 buccal filmPhase 2Treatment Resistant DepressionPsychiatryJul 2026

Targets

GRIN1 (1)

Companies with the same targets

Syndeio Biosciences GRIN Therapeutics SHINKEI Therapeutics Aptinyx Arialys Australia Johnson & Johnson (Janssen)

Companies built like this

Arialys Australia SyneuRx International (Taiwan) Syndeio Biosciences NeuroRx Bazelet Nehushtan

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.